₦525,000 ₦630,000
Human Immunoglobulin (IVIG) is a pharmaceutical-grade, highly purified sterile solution of concentrated antibodies (predominantly IgG) derived from pooled human plasma. It provides a stable clinical tool for supplying the body with a broad spectrum of antibodies to neutralize pathogens and modulate the immune system. This 10% high-concentration formula is specifically engineered to clear the path for shorter infusion times and lower volume loads, which is clinically significant for patient comfort and systemic safety in the Nigerian medical environment.
Active Ingredient: Human Normal Immunoglobulin (IgG) 100mg/mL (10%)
Product Type: Blood Product / Immunomodulator
Formulation: Ready-to-use Liquid Solution
Route: Intravenous (IV) Infusion
Pack Size: 10g/100mL, 5g/50mL, or 2.5g/25mL Vials (Typical)
Availability: Prescription-Only Medicine (POM) — Strict clinical supervision required.
Various Specialized Biopharmaceutical Providers (e.g., Reliance Life Sciences, Baxter, Grifols) — Produced under stringent systemic viral inactivation and purification protocols to ensure molecular stability and localized safety.
Human Immunoglobulin 10% is primarily indicated as replacement therapy for patients with systemic primary immunodeficiency (PID) or localized secondary immunodeficiency (SID) who suffer from recurrent infections. Clinically, it is also used for its systemic immunomodulatory effects in treating autoimmune disorders such as Primary Immune Thrombocytopenia (ITP), Guillain-Barré Syndrome, Kawasaki Disease, and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). By supplying immediate passive immunity, it assists the body in clearing the path for recovery from severe systemic inflammatory states.
Thrombosis Risk: IVIG products can systemically increase the risk of blood clots. Use with extreme caution in patients with localized histories of heart disease, hypertension, or those who are bedridden.
Renal Dysfunction: Systemic infusion has been linked to acute localized kidney failure, particularly in products containing sucrose (though most 10% solutions are sugar-free). Monitor localized urine output and creatinine levels closely.
Aseptic Meningitis: Some patients may develop systemic symptoms like severe headache, neck stiffness, and light sensitivity (AMS) within 48 hours of infusion.
IgA Deficiency: Patients with localized selective IgA deficiency and antibodies against IgA are at a high systemic risk of life-threatening anaphylactic reactions.
This medication must be administered systemically by a healthcare professional in a clinical setting. The standard localized infusion rate begins slowly (typically 0.5 mL/kg/hr) for the first 30 minutes to clear the path for systemic tolerance. If well-tolerated, the rate may be gradually increased to a maximum (often up to 6–8 mL/kg/hr). Dosage is strictly individualized based on systemic body weight and the specific clinical indication. Ensure adequate hydration prior to the systemic infusion to reduce localized renal stress.
Commonly reported effects during or shortly after infusion include localized headache, systemic fever, chills, and nausea. These are often localized clinical signs of a fast infusion rate. Delayed systemic effects can include myalgia (muscle pain), localized skin rash, or fatigue. Consult your doctor immediately if you experience localized chest pain, systemic shortness of breath, or sudden localized swelling of the legs after treatment.
Store in a refrigerator at 2°C to 8°C. Do not freeze. In the Nigerian climate, systemic potency is highly sensitive to localized heat; the product should be removed from the refrigerator only shortly before infusion. Protect the localized vial from light by keeping it in its original systemic carton. Once a vial is punctured, the contents should be used systemically within a few hours or discarded to ensure localized sterility.
Q: Can I receive live vaccines while on IVIG?
A: No. Systemic IVIG can interfere with the localized immune response to live vaccines (like Measles or Mumps). Wait at least 3 months after your last systemic dose.
Q: Why is the 10% solution preferred over lower concentrations?
A: The 10% concentration systemically delivers the same amount of antibodies in half the localized volume of a 5% solution, which is clinically better for the heart and kidneys.
Q: Is this product safe from viruses?
A: Yes. The manufacturing process includes multiple systemic steps specifically designed to clear the path for the inactivation and removal of localized viruses and pathogens.
Q: Does it require a prescription at Sanlive Pharmacy?
A: Yes. This is a high-risk systemic biological product. A valid doctor’s prescription and clinical monitoring are mandatory for every localized purchase.
Human Immunoglobulin 10% is a Prescription-Only Medicine. A valid doctor's prescription is required. Our licensed pharmacists are available to provide guidance on localized cold-chain maintenance and systemic clinical documentation.
Verified Cold-Chain Integrity: We guarantee 100% stable 2°C–8°C storage to protect systemic molecular activity from the Nigerian heat.
Authentic Biologicals: We source only from licensed global distributors with verified NAFDAC registration and systemic purity.
Expert Support: Access to licensed pharmacists for guidance on managing localized infusion protocols and systemic safety.
Secure Delivery: Reliable and specialized cold-chain shipping of essential biological treatments nationwide across Nigeria.
Order Human Immunoglobulin 10% from Sanlive Pharmacy for immune support and fast delivery.
No reviews yet.
Login to write a review.
Related Products
.jpg)
